National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$44.00
add to cart

Rights & Permissions

topleft topright

Rare Diseases and Orphan Products: Accelerating Research and Development (2011)
Board on Health Sciences Policy (HSP)

Citation Manager

. "Appendix C: Medicare Part D Coverage and Reimbursement of Orphan Drugs." Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press, 2011.

Please select a format:

BibTeX EndNote RefMan


Page
329
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Rare Diseases and Orphan Products: Accelerating Research and Development

Exclusivity Start Date

Generic Name

Trade Name

Indication for Original Approvala

6/10/04

Glutamine

Nutrestore

Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication

8/12/05

Quinine sulfate

Qualaquin

Treatment of uncomplicated Plasmodium falciparum malaria

10/28/05

Nelarabinec,d

Arranon

Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens

11/2/05

Deferasirox

Exjade

Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older

12/20/05

Sorafenib

Nexavar

Treatment of patients with advanced renal cell carcinoma

12/27/05

Lenalidomide

Revlimid

Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities

3/1/06

Cetuximabc,d,e

Erbitux

For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed

3/29/06

Tacrolimusb,c

Prograf

Prophylaxis of organ rejection in patients receiving allogenic heart transplants

4/28/06

Recombinant human acid alpha-glucosidasec,e

Myozyme

For use in patients with Pompe disease (GAA deficiency)

5/2/06

Decitabinec

Dacogen

For treatment of patients with myelodysplastic syndromes

Page
329